检索结果-南通市图书馆

Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma:a single-institution experience

引用

Oncology Research 2024年第6期32卷 1031-1036页

作者： CONSTANTINE N.LOGOTHETIS NATHAN P.HORVAT TONY KURIAN CELESTE BELLO JULIO CHAVEZ LEIDY ISENALUMHE BIJAL SHAH LUBOMIR SOKOL HAYDER SAEED JAVIER PINILLA SAMEH GABALLA Department of Internal Medicine University of South FloridaTampaFL33602USA College of Medicine University of South Florida MorsaniTampaFL33602USA H.Lee Moffitt Cancer Center and Research Institute TampaFL33612USA

extranodal marginal zone lymphoma(EMZL)encompasses 70%of cases of marginal zone *** bendamustine and rituximab(BR)were derived from trials involving other indolent non-Hodgkin’s *** one trial has evaluated frontline BR prospectively in *** retrospective study reports outcomes among EMZL patients receiving frontline ***-five patients were included with a median age of 69 years(40–81).Five(20.0%)patients had stage Ⅰ/Ⅱ disease,and 20(80.0%)had stage Ⅲ/Ⅳ *** median number of cycles was 6.0(3.0–6.0).Maintenance rituximab was administered to 10(41.7%)*** response rate(ORR)was 100.0%(60.0%complete response,40.0%partial response).Medians of overall survival and progression-free survival were not *** estimated 2-year progression-free survival was 85.2%and overall survival was 100.0%.Four(16.6%)patients had infections related to treatment;3(12.0%)transformed to diffuse large B-cell lymphoma;5(20.8%)had a relapse or progression of EMZL;and 3(12.0%)died unrelated to *** is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature.

关键词： extranodal marginal zone lymphoma Bendamustine Rituximab Front-line therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Classification, diagnosis, and management of conjunctival lymphoma

引用

Eye and Vision 2019年第1期6卷 175-190页

作者： Rebecca E.Tanenbaum Anat Galor Sander R.Dubovy Carol L.Karp Department of Ophthalmology Bascom Palmer Eye InstituteUniversity of Miami Miller School of Medicine900 NW 17th St.MiamiMiamiFL 33136USA

lymphoma is a malignant lymphoproliferative tumor that can involve the *** 5–15%of all extranodal lymphomas are found in the ocular adnexal region,with approximately 25%of those involving the ***-eight percent of conjunctival lymphomas arise from *** most common subtype of conjunctival lymphoma is extranodal marginal zone lymphoma(80%),followed by follicular lymphoma(8%),diffuse large B-cell lymphoma(3%)and mantle cell lymphoma(3%).Natural killer and T cells(NK/T)are rare causes of *** most conjunctival lymphomas are localized to the ocular adnexa at the time of presentation,systemic examination and management are of key importance in the long-term care of the *** review outlines the classification,etiology,presentation,diagnosis,and management of conjunctival *** novel use of high resolution optical coherence tomography,both as a diagnostic tool and as a means for ongoing evaluation during treatment,is *** options discussed include external beam radiation,chemotherapy,immunotherapy,antibiotic therapy,and combination *** investigation of the etiology and pathogenesis of conjunctival lymphoma is expected to reveal opportunities for innovative and individualized therapeutic *** between multiple disciplines is key in the advancement of the field.

关键词： Conjunctiva Conjunctival tumor extranodal marginal zone lymphoma lymphoma Optical coherence tomography Salmon patch

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

marginal zone lymphoma with severe rashes: A case report

引用

World Journal of Clinical Cases 2024年第3期12卷 565-574页

作者： Si-Jun Bai Ye Geng Yi-Nan Gao Cai-Xia Zhang Qian Mi Chen Zhang Jia-Ling Yang Si-Jie He Zhen-YingYan Jian-Xia He Department of Hematology Shanxi Provincial People’s HospitalTaiyuan 030012Shanxi ProvinceChina

BACKGROUND marginal zone lymphoma(MZL)is an indolent subtype of non-Hodgkin lymphoma(NHL),which is rare clinically with severe rashes as the initial *** SUMMARY This study reports a case of MZL with generalized skin rashes accompanied by pruritus and purulent ***-line treatment with rituximab combined with zanubrutinib had poor ***,after switching to obinutuzumab combined with zanubrutinib,the case was alleviated,and the rashes *** For patients with advanced stage MZL not benefiting from type I anti-CD20 monoclonal antibody(mAb)combination therapy,switching to a type II anti-CD20 mAb combination regimen may be *** approach may provide a new perspective in the treatment of MZL.

关键词： marginal zone lymphoma Mucosa-associated lymphoid tissue extranodal marginal zone lymphoma Primary cutaneous marginal zone lymphoma Rituximab,Obinutuzumab Zanubrutinib Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：